<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Phys Ther Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Phys Ther Sci</journal-id><journal-id journal-id-type="publisher-id">JPTS</journal-id><journal-title-group><journal-title>Journal of Physical Therapy Science</journal-title></journal-title-group><issn pub-type="ppub">0915-5287</issn><issn pub-type="epub">2187-5626</issn><publisher><publisher-name>The Society of Physical Therapy Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25642068</article-id><article-id pub-id-type="pmc">4305556</article-id><article-id pub-id-type="publisher-id">jpts-2014-361</article-id><article-id pub-id-type="doi">10.1589/jpts.27.179</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Bone mineral density evaluation of patients with type 2 diabetes
mellitus</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Adil</surname><given-names>Camli</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ayd&#x00131;n</surname><given-names>Teoman</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ta&#x0015f;p&#x00131;nar</surname><given-names>&#x000d6;zg&#x000fc;r</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref rid="cor1" ref-type="corresp"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>K&#x00131;z&#x00131;ltan</surname><given-names>Huriye</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eri&#x0015f;</surname><given-names>Ali Hikmet</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hocaoglu</surname><given-names>Ilknur Turk</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Po&#x0015f;ul</surname><given-names>Sevde</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kepekci</surname><given-names>Muge</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Denizli</surname><given-names>Ebru</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>G&#x000fc;ler</surname><given-names>Mustafa</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1)</label> Department of Internal Medicine, Faculty of Medicine, Bezmi
Alem Vak&#x00131;f University, Turkey</aff><aff id="aff2"><label>2)</label> Department of Physical Medicine and Rehabilitation: Istanbul, Turkey</aff><aff id="aff3"><label>3)</label> Department of Radiation Oncology, Faculty of Medicine,
Bezmi Alem Vak&#x00131;f University, Turkey</aff><aff id="aff4"><label>4)</label> Frans&#x00131;z Lape Hospital, Turkey</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Ozgur Taspinar, Department of Physical Medicine and Rehabilitation, Faculty
of Medicine, Bezmi Alem Vak&#x00131;f University: Istanbul, Turkey. (E-mail: <email xlink:href="drozgur82@gmail.com">drozgur82@gmail.com</email>)</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>1</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2015</year></pub-date><volume>27</volume><issue>1</issue><fpage>179</fpage><lpage>182</lpage><history><date date-type="received"><day>02</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>03</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>2015&#x000a9;by the Society of Physical Therapy Science</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p></license></permissions><abstract><p>[Purpose] Diabetes mellitus is a metabolic disorder resulting from a defect in insulin
secretion, insulin action, or both. A consequence of this is chronic hyperglycemia with
disturbances in carbohydrate, fat and protein metabolism. We investigated whether there is
any difference among DM patients and a control group in terms of lumbar and femur BMD
(bone mineral density), and standard deviation scores (Z score and T score). [Subjects and
Methods] This randomized, prospective, controlled, single-blind study was conducted in the
Physical Medicine and Rehabilitation Department Faculty of Medicine, Bezm-i Alem Vak&#x00131;f
University. Patients with type 2 diabetes mellitus were included in the patient groups.
Healthy individuals were included in the control group. [Results] A total of 126 patients
completed the study (63 in the study group, 63 in the control group). There was no
significant difference in the results of the laboratory examinations of the cases. The
bone mineral densities of the cases were found to be significantly low in terms of the
lumbar (L1&#x02013;4) T scores in the type 2 diabetes group. [Conclusion] Although osteoporosis is
one of the potential complications of type 1 diabetes, its effect on bone mineral density
in type 2 DM is controversial. In different studies, the bone mineral density values have
increased, decreased or remained normal. With the exception of the lumbar (L1&#x02013;4) T score,
similar results were obtained in this study.</p></abstract><kwd-group><title>Key words</title><kwd>Type 2 diabetes mellitus</kwd><kwd>Osteoporosis</kwd><kwd>Bone mineral density</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion,
insulin action, or both. A consequence of this is chronic hyperglycemia with disturbances in
carbohydrate, fat, and protein metabolism. Diabetes mellitus (DM) is a common disorder of
carbohydrate, fat, and protein metabolism reflected by inappropriate high fasting and
postprandial glucose levels (hyperglycemia). This ailment results from the absence or
scantiness of insulin secretion with or without concurrent impairment of insulin action.
Consequently, the disease was classified into two types known as type&#x02005;I&#x02005;(insulin dependent,
IDDM) and II (non-insulin dependent, NIDDM) according to the degree of pancreatic defect.
This classification has been even recognized since the time of Ibn Sinaa, who mentioned it
in his book &#x0201c;The Canon of Medicine&#x0201d;.</p><p>DM is not confined to abnormal blood glucose levels but progresses to affect other body
systems. This fact has been confirmed by several epidemiological studies and clinical trials
that have linked hyperglycemia to several complications at the macrovascular (coronary
artery disease and cerebrovascular disease) and microvascular levels (renal failure,
blindness, limb amputation, neurological complications and premature death)<xref rid="r1" ref-type="bibr">1</xref><sup>)</sup>.</p><p>Endocrine and metabolic alterations in diabetes mellitus can trigger disorders of calcium
homeostasis, skeletal metabolism, and bone mass<xref rid="r1" ref-type="bibr">1</xref><sup>)</sup>. It is reported that more than of 50% type 1 diabetes patients have
osteoporosis (OP), which is called diabetic osteoporosis (DO), a reduced bone mass and an
increased fracture risk shown to occur in type 1 diabetes mellitus<xref rid="r2" ref-type="bibr">2</xref><sup>)</sup>. On the other hand, in type 2 diabetes, several but not all
cross-sectional studies have found normal<xref rid="r3" ref-type="bibr">3</xref><sup>)</sup>
or elevated<xref rid="r4" ref-type="bibr">4</xref><sup>)</sup> bone mass, and these results
are surprising given the increased fracture risk associated with type 2 diabetes<xref rid="r5" ref-type="bibr">5</xref><sup>)</sup>. In type 2 DM patients complicated with OP,
there is a larger decrease in bone formation than bone resorption in compared with the case
of postmenopausol OP, and this mainly influences the indexes of bone formation and may be a
lower turnover ratio type.</p><p>We investigated whether there is any difference among DM patients and a control group in
terms of lumbar and femur BMD (bone mineral density) and standard deviation scores (Z score
and T score).</p></sec><sec sec-type="methods" id="s2"><title>SUBJECTS AND METHODS</title><p>This randomized, prospective, controlled, single-blind study was conducted in Physical
Medicine and Rehabilitation Department Faculty of Medicine, Bezm-i Alem Vak&#x00131;f University.
Patients with type 2 diabetes mellitus were included in the patient groups. Healthy
individuals were included in the control group. In addition to their demographic
characteristics (age, gender, weight, height, body mass index [BMI]), waist circumference,
hip circumference, waist/hip proportion, used medicines, body muscle masses, fat masses, and
fat percentages were obtained. The patients included in this study were between the ages of
40 and 65. The control group in this study consisted of healthy individuals.</p><p>All the recruited subjects signed informed consent forms before participating in the study,
and approval of a local ethics committee was obtained. The exclusion characteristics were
early menopause, hormone replacement therapy, usage of medicines able to affect BMD
(thiazide diuretics, statins, anticoagulants, antiepileptics), diseases affecting bone
metabolism (hypo/hyperthyroid, Cushing syndrome, primary hiperparathyroidism, renal failure,
liver disease, inflammatory bowel disease, malabsorption), alcoholism, osteoporotic breakage
history, scoliosis.</p><p>The medicines taken by the patients, and their disease durations were recorded. Data about
the presence of diabetic complications (retinopathy, ischemic cardiac disease, hypertension,
neuropathy, nephropathy) were regularly recorded in during follow-up. The whole blood count,
fasting blood glucose, urea, creatine, C-reactive protein, HbA1c (glycolysed hemoglobin),
alkaline phosphatase (ALP), calcium (Ca), phosphor (P) levels, and erythrocyte sedimentation
rate (ESR) were examined, and a 24-h urinalysis was carried out.</p><p>Through dual-energy X-ray absorptiometry (DEXA, DPX-LUNAR), BMD measurements of the lumbar
spine (anteroposterior projection of L1-L4) and left proximal femur (total score) were
executed. The BMD data are presented in g/cm<sup>2</sup> and standard deviation scores (Z
and T scores). T scores between &#x02212;1 and &#x02212;2.5 were considered to indicate osteopenia, and
those equal or below &#x02212;2.5 were considered to indicate osteoporosis (WHO Study Group,
1994).</p><p>The calculations were performed using the Statistical Package for Social Sciences for
Windows software version 16.0 (SPSS Inc., Chicago, IL, USA). The Kolmogorov-Smirnov test was
used to confirm that data within the ranges of the normal distribution in both groups. A
nonparametric test was employed for the variables outside the normal distribution. The
comparison of the data between the groups was carried out with the Mann-Whitney U-test. The
Wilcoxon signed-rank test was used to examine the pre- and post- exercise differences within
groups. Statistical significance was based on a value of p &#x0003c; 0.05 with a 95% confidence
interval.</p></sec><sec sec-type="results" id="s3"><title>RESULTS</title><p>A total of 126 patients completed the study (63 in the study group, 63 in the control
group). The clinical and demographic characteristics of the patients and the healthy
controls are listed in <xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Clinical and demographic characteristics of patient and control groups (mean &#x000b1; SD
or n, %)</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">DM group<break/>(n=63)</th><th valign="top" align="center" rowspan="1" colspan="1">Control group<break/>(n=63)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">60.1&#x000b1;8.5</td><td align="center" valign="top" rowspan="1" colspan="1">58.4&#x000b1;7.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male patients (n, %)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (46%)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (47%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (cm/kg<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">32.4&#x000b1;4.8</td><td align="center" valign="top" rowspan="1" colspan="1">28.4&#x000b1;5.5</td></tr></tbody></table><table-wrap-foot><p>DM: diabetes mellitus; SD: standard deviation. p &#x0003c; 0.05 is significant</p></table-wrap-foot></table-wrap>. The mean age was 59.31 &#x000b1; 8.17&#x02005;years. The mean disease duration was
11.42&#x000b1;2.82&#x02005;years. There was no significant difference in the result of the laboratory
examinations of the cases (<xref rid="tbl_002" ref-type="table">Table 2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Clinical and demographic characteristics of patient and control groups (mean &#x000b1; SD
or n, %)</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">DM group<break/>(n=63)</th><th valign="top" align="center" rowspan="1" colspan="1">Control group<break/>(n=63)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Ca (mg/dl)</td><td align="center" valign="top" rowspan="1" colspan="1">8.8&#x000b1;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">8.5&#x000b1;0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P (mg/dl)</td><td align="center" valign="top" rowspan="1" colspan="1">4.2&#x000b1;0.8</td><td align="center" valign="top" rowspan="1" colspan="1">4.3&#x000b1;0.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALP (U/l)</td><td align="center" valign="top" rowspan="1" colspan="1">85.9+26.7</td><td align="center" valign="top" rowspan="1" colspan="1">84.4+32.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fasting blood glucose (mg/dl)</td><td align="center" valign="top" rowspan="1" colspan="1">162.4&#x000b1;44.8</td><td align="center" valign="top" rowspan="1" colspan="1">98.4&#x000b1;15.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">24-h urea Ca</td><td align="center" valign="top" rowspan="1" colspan="1">143.8&#x000b1;81.1</td><td align="center" valign="top" rowspan="1" colspan="1">133.8&#x000b1;55.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Urea (mg/dl)</td><td align="center" valign="top" rowspan="1" colspan="1">48&#x000b1;11.2</td><td align="center" valign="top" rowspan="1" colspan="1">42&#x000b1;8.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatine (mg/dl)</td><td align="center" valign="top" rowspan="1" colspan="1">0.9&#x000b1;0.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.7&#x000b1;0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ESR</td><td align="center" valign="top" rowspan="1" colspan="1">15.6&#x000b1;8.2</td><td align="center" valign="top" rowspan="1" colspan="1">18.1&#x000b1;7.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP</td><td align="center" valign="top" rowspan="1" colspan="1">0.2&#x000b1;0.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.1&#x000b1;0.5 </td></tr></tbody></table><table-wrap-foot><p>DM: diabetes mellitus; SD: standard deviation. p &#x0003c; 0.05 is significant</p></table-wrap-foot></table-wrap>). The bone mineral densities of the cases are presented in <xref rid="tbl_003" ref-type="table">Table 3</xref><table-wrap id="tbl_003" orientation="portrait" position="float"><label>Table 3.</label><caption><title>BMD, Z and T scores of patient and control groups (mean &#x000b1; SD or n, %)</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">DM group<break/>(n=63)</th><th valign="top" align="center" rowspan="1" colspan="1">Control group<break/>(n=63)</th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Lumbar (L1&#x02013;4) BMD</td><td align="center" valign="top" rowspan="1" colspan="1">46.6&#x000b1;205.4</td><td align="center" valign="top" rowspan="1" colspan="1">1.1&#x000b1;0.1</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lumbar (L1&#x02013;4) T Score</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.9&#x000b1;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.01&#x000b1;1.7</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lumbar (L1&#x02013;4) Z Score</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.01&#x000b1;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.1&#x000b1;1.2</td><td align="center" valign="top" rowspan="1" colspan="1"><sup>&#x000a5;</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total femur BMD</td><td align="center" valign="top" rowspan="1" colspan="1">14.9&#x000b1;110.6</td><td align="center" valign="top" rowspan="1" colspan="1">1.0&#x000b1;0.1</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total femur T Score</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.2&#x000b1;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.0&#x000b1;1.2</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total femur Z Score</td><td align="center" valign="top" rowspan="1" colspan="1">0.5&#x000b1;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.1&#x000b1;1.3</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>DM: diabetes mellitus; SD: standard deviation. <sup>&#x000a5;</sup>p &#x0003c; 0.05 is
significant.</p></table-wrap-foot></table-wrap>. Regarding the medications taken by the diabetic patients, 48 patients were
using oral antidiabetic, and 8 patients were using insulin, and 7 patients were using both
of them. With regard to the disease durations, there were 23 patients in the 0&#x02013;5 year group
(36.5%), 17 patients in the 6&#x02013;10 year group (27%), 14 patients in the 11&#x02013;15 year group
(22.2%), 4 patients in the 16&#x02013;20 year group (6.3%), 1 patient in the 21&#x02013;25 year group
(1.6%), and 4 patients in the 26&#x02013;30 year group (6.3%). No significant correlation was
detected when comparing disease durations and the bone marrow densities of the Type 2 DM
patients by the medicines taken (p&#x0003e;0.050) (<xref rid="tbl_004" ref-type="table">Table
4</xref><table-wrap id="tbl_004" orientation="portrait" position="float"><label>Table 4.</label><caption><title>BMD, Z and T scores of drug usages of diabetic patients (mean &#x000b1; SD or n,
%)</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">Oral antidiabetic<break/>(n=48)</th><th valign="top" align="center" rowspan="1" colspan="1">Insulin<break/>(n=15)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Lumbar (L1&#x02013;4) BMD</td><td align="center" valign="top" rowspan="1" colspan="1">53.6&#x000b1;195.4</td><td align="center" valign="top" rowspan="1" colspan="1">42.3&#x000b1;180.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lumbar (L1&#x02013;4) T Score</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.6&#x000b1;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.8&#x000b1;1.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lumbar (L1&#x02013;4) Z Score</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.04&#x000b1;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.0&#x000b1;1.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total femur BMD</td><td align="center" valign="top" rowspan="1" colspan="1">14.9&#x000b1;110.6</td><td align="center" valign="top" rowspan="1" colspan="1">13.0&#x000b1;100.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total femur T Score</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.2&#x000b1;1.1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.1&#x000b1;1.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total femur Z Score</td><td align="center" valign="top" rowspan="1" colspan="1">0.5&#x000b1;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.5&#x000b1;1.2</td></tr></tbody></table><table-wrap-foot><p>DM: diabetes mellitus; SD: standard deviation. p &#x0003c; 0.05 is significant</p></table-wrap-foot></table-wrap>).</p></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>The most important aim of our study was to compare the bone mineral densities of type 2
diabetes mellitus patients with those of a normal, healthy population. In our examinations,
we determined that there was a significant decrease in the lumbar region T score in compared
with the normal population.</p><p>Although osteoporosis is one of the complications of type 1 diabetes, the effect of type 2
DM on bone mineral density is controversial. In different studies, the BMD values in type 2
DM have increased<xref rid="r6" ref-type="bibr">6</xref><sup>)</sup>, decreased<xref rid="r7" ref-type="bibr">7</xref><sup>)</sup>, or stayed normal<xref rid="r8" ref-type="bibr">8</xref><sup>)</sup>. In general, the type 2 DM patients with low BMD values have
been observed to have long-term diabetes and menopause, to have poor glucose control, and to
have disordered renal functions<xref rid="r9" ref-type="bibr">9</xref><sup>)</sup>.
Furthermore, in some studies, it has been concluded that diabetic women are protected from
osteopenia<xref rid="r10" ref-type="bibr">10</xref><sup>)</sup>. This can be explained in
type 2 DM, unlike the case of type 1 DM, by the frequent observation of obesity due to
increased insulin resistance and the higher of osteoarthritis in DM patients<xref rid="r11" ref-type="bibr">11</xref><sup>)</sup>.</p><p>In the study of Sosa et al., 47 female type 2 DM patients and 252 nondiabetic women were
compared in terms of BMD through DEXA and quantitative computerized tomography, and no
significant difference was detected<xref rid="r12" ref-type="bibr">12</xref><sup>)</sup>. In
the literature, it has been found that type 2 DM patients, individuals using a dietary and
oral antidiabetic, and individuals taking insulin have lower BMD values<xref rid="r13" ref-type="bibr">13</xref><sup>)</sup>. It has been asserted that better glysemic control,
exercise, diet, and medical therapy can decrease the complications in DM<xref rid="r14" ref-type="bibr">14</xref><sup>)</sup>. But in our study, no difference could be
determined in BMD in relation to medicine usage.</p><p>In measurements from the calcaneal region, a previous study reported higher BMD values in
postmenapousal women and similar values to those of a control group in diabetic men, and it
has been determined that there was no difference between women and men<xref rid="r15" ref-type="bibr">15</xref><sup>)</sup>.</p><p>Many mechanisms have been asserted to contribute to diabetic osteopenia. One of them is
that it can lead to diabetic osteopenia due to deficiency in anabolic activation of
insulin<xref rid="r13" ref-type="bibr">13</xref><sup>)</sup>. Another mechanism asserted
in diabetic osteopenia is suppression of osteoblastic bone formation<xref rid="r16" ref-type="bibr">16</xref><sup>)</sup>. In previous studies, it has been shown that decreases in
osteoblastic functions occurred in diabetic ostopenia<xref rid="r17" ref-type="bibr">17</xref><sup>)</sup>. Previous studies have also shown that the bone cycle speed in type
2 DM is much slower than that in healthy postmenopausal patients<xref rid="r18" ref-type="bibr">18</xref><sup>)</sup>. In another study on type 1 and type 2 diabetes patients,
it has been underlined that the decrease in bone mass can be related with decrease in bone
formation and microangiopathy in bone tissue<xref rid="r19" ref-type="bibr">19</xref><sup>)</sup>. In histopathologic examination of type 2 DM patients, the
osteoblast surface, cortical thickness, osteoid thickness, osteoid volume, and bone volume
have been found to be lower in diabetic patients. It has been concluded that the mechanism
laying behind the diabetic osteopenia can be the decrease of quantitative osteoid, the
decrease of osteoblasts, and finally the decrease of bone cycle<xref rid="r17" ref-type="bibr">17</xref><sup>)</sup>. In DM patients, chronic hyperglycaemia decreases
estradiol synthesis by causing ovarian damage. Estradiol has a direct stimulatory effect on
osteoblasts, and this may contribute to osteoporosis<xref rid="r20" ref-type="bibr">20</xref><sup>)</sup>.</p><p>As a result, the BMD measurements the postmenopausal women with Type 2 Diabetes Mellitus in
the present study did not show any difference in proportion to those of the control
group.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>Carnevale</surname><given-names>V</given-names></name><name><surname>Romagnoli</surname><given-names>E</given-names></name><name><surname>D&#x02019;Erasmo</surname><given-names>E</given-names></name></person-group>: <article-title>Skeletal involvement in patients with diabetes
mellitus</article-title>. <source>Diabetes Metab Res Rev</source>, <year>2004</year>,
<volume>20</volume>: <fpage>196</fpage>&#x02013;<lpage>204</lpage>. <pub-id pub-id-type="pmid">15133750</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Nicodemus</surname><given-names>KK</given-names></name><name><surname>Folsom</surname><given-names>AR</given-names></name></person-group>, Iowa Women&#x02019;s Health Study: <article-title>Type 1 and type 2 diabetes and
incident hip fractures in postmenopausal women</article-title>. <source>Diabetes
Care</source>, <year>2001</year>, <volume>24</volume>:
<fpage>1192</fpage>&#x02013;<lpage>1197</lpage>. <pub-id pub-id-type="pmid">11423501</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Isaia</surname><given-names>GC</given-names></name><name><surname>Ardissone</surname><given-names>P</given-names></name><name><surname>Di Stefano</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>: <article-title>Bone metabolism in type 2 diabetes
mellitus</article-title>. <source>Acta Diabetol</source>, <year>1999</year>,
<volume>36</volume>: <fpage>35</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="pmid">10436250</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Hanley</surname><given-names>DA</given-names></name><name><surname>Brown</surname><given-names>JP</given-names></name><name><surname>Tenenhouse</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>Canadian Multicentre Osteoporosis Study Research Group:
<article-title>Associations among disease conditions, bone mineral density, and
prevalent vertebral deformities in men and women 50 years of age and older:
cross-sectional results from the Canadian Multicentre Osteoporosis
Study</article-title>. <source>J Bone Miner Res</source>, <year>2003</year>,
<volume>18</volume>: <fpage>784</fpage>&#x02013;<lpage>790</lpage>. <pub-id pub-id-type="pmid">12674340</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Ottenbacher</surname><given-names>KJ</given-names></name><name><surname>Ostir</surname><given-names>GV</given-names></name><name><surname>Peek</surname><given-names>MK</given-names></name><etal>et al.</etal></person-group>: <article-title>Diabetes mellitus as a risk factor for hip fracture in
mexican american older adults</article-title>. <source>J Gerontol A Biol Sci Med
Sci</source>, <year>2002</year>, <volume>57</volume>:
<fpage>M648</fpage>&#x02013;<lpage>M653</lpage>. <pub-id pub-id-type="pmid">12242318</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Sahin</surname><given-names>G</given-names></name><name><surname>Ba&#x0011f;is</surname><given-names>S</given-names></name><name><surname>Cimen</surname><given-names>OB</given-names></name><etal>et al.</etal></person-group>: <article-title>Lumbar and femoral bone mineral density in type 2 Turkish
diabetic patients</article-title>. <source>Acta Med (Hradec Kralove)</source>,
<year>2001</year>, <volume>44</volume>: <fpage>141</fpage>&#x02013;<lpage>143</lpage>.
</mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Saneshige</surname><given-names>S</given-names></name></person-group>: <article-title>[Spinal bone mineral density in the female diabetic
patients]</article-title>. <source>Nippon Ronen Igakkai Zasshi</source>,
<year>1992</year>, <volume>29</volume>: <fpage>864</fpage>&#x02013;<lpage>873</lpage>.
<pub-id pub-id-type="pmid">1491483</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Weinstock</surname><given-names>RS</given-names></name><name><surname>Goland</surname><given-names>RS</given-names></name><name><surname>Shane</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>: <article-title>Bone mineral density in women with type II diabetes
mellitus</article-title>. <source>J Bone Miner Res</source>, <year>1989</year>,
<volume>4</volume>: <fpage>97</fpage>&#x02013;<lpage>101</lpage>. <pub-id pub-id-type="pmid">2718784</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Kao</surname><given-names>CH</given-names></name><name><surname>Tsou</surname><given-names>CT</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><etal>et al.</etal></person-group>: <article-title>Bone mineral density in patients with noninsulin-dependent
diabetes mellitus by dual photon absorptiometry</article-title>. <source>Nucl Med
Commun</source>, <year>1993</year>, <volume>14</volume>:
<fpage>373</fpage>&#x02013;<lpage>377</lpage>. <pub-id pub-id-type="pmid">8510877</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Buysschaert</surname><given-names>M</given-names></name><name><surname>Cauwe</surname><given-names>F</given-names></name><name><surname>Jamart</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>: <article-title>Proximal femur density in type 1 and 2 diabetic
patients</article-title>. <source>Diabete Metab</source>, <year>1992</year>,
<volume>18</volume>: <fpage>32</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="pmid">1563534</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Sieradzki</surname><given-names>J</given-names></name><name><surname>Trznadel-Morawska</surname><given-names>I</given-names></name><name><surname>Olszanecki</surname><given-names>P</given-names></name></person-group>: <article-title>[Bone density in type 2 diabetes as related to obesity and
adrenal function]</article-title>. <source>Pol Arch Med Wewn</source>,
<year>1998</year>, <volume>100</volume>: <fpage>125</fpage>&#x02013;<lpage>132</lpage>.
<pub-id pub-id-type="pmid">10101927</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>Sosa</surname><given-names>M</given-names></name><name><surname>Dominguez</surname><given-names>M</given-names></name><name><surname>Navarro</surname><given-names>MC</given-names></name><etal>et al.</etal></person-group>: <article-title>Bone mineral metabolism is normal in non-insulin-dependent
diabetes mellitus</article-title>. <source>J Diabetes Complications</source>,
<year>1996</year>, <volume>10</volume>: <fpage>201</fpage>&#x02013;<lpage>205</lpage>.
<pub-id pub-id-type="pmid">8835919</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Koci&#x000e1;n</surname><given-names>J</given-names></name><name><surname>Brunov&#x000e1;</surname><given-names>J</given-names></name></person-group>: <article-title>[Diabetic osteopathy. 4. Laboratory
findings]</article-title>. <source>Vnitr Lek</source>, <year>1990</year>,
<volume>36</volume>: <fpage>460</fpage>&#x02013;<lpage>466</lpage>. <pub-id pub-id-type="pmid">2375077</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Smith</surname><given-names>LL</given-names></name><name><surname>Burnet</surname><given-names>SP</given-names></name><name><surname>McNeil</surname><given-names>JD</given-names></name></person-group>: <article-title>Musculoskeletal manifestations of diabetes
mellitus</article-title>. <source>Br J Sports Med</source>, <year>2003</year>,
<volume>37</volume>: <fpage>30</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="pmid">12547740</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>P&#x000e9;rez-Castrill&#x000f3;n</surname><given-names>JL</given-names></name><name><surname>De Luis</surname><given-names>D</given-names></name><name><surname>Martin-Escurado</surname><given-names>JC</given-names></name><etal>et al.</etal></person-group>: <article-title>Non-insulin-dependent diabetes, bone mineral density, and
cardiovasculer risk factors</article-title>. <source>Diabetes Complications</source>,
<year>2004</year>, <volume>18</volume>: <fpage>317</fpage>&#x02013;<lpage>321</lpage>.
</mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Takizawa</surname><given-names>M</given-names></name><name><surname>Kameyama</surname><given-names>K</given-names></name><name><surname>Maruyama</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>: <article-title>[Bone loss in type 2 diabetes mellitus&#x02014;diabetic
osteopenia]</article-title>. <source>Nihon Rinsho</source>, <year>2003</year>,
<volume>61</volume>: <fpage>287</fpage>&#x02013;<lpage>291</lpage>. <pub-id pub-id-type="pmid">12638223</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Leite Duarte</surname><given-names>ME</given-names></name><name><surname>da Silva</surname><given-names>RD</given-names></name></person-group>: <article-title>[Histomorphometric analysis of the bone tissue in patients
with non-insulin-dependent diabetes (DMNID)]</article-title>. <source>Rev Hosp Clin Fac
Med Sao Paulo</source>, <year>1996</year>, <volume>51</volume>:
<fpage>7</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="pmid">8762647</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Akin</surname><given-names>O</given-names></name><name><surname>G&#x000f6;l</surname><given-names>K</given-names></name><name><surname>Akt&#x000fc;rk</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>: <article-title>Evaluation of bone turnover in postmenopausal patients
with type 2 diabetes mellitus using biochemical markers and bone mineral density
measurements</article-title>. <source>Gynecol Endocrinol</source>, <year>2003</year>,
<volume>17</volume>: <fpage>19</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="pmid">12724015</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Leidig-Bruckner</surname><given-names>G</given-names></name><name><surname>Ziegler</surname><given-names>R</given-names></name></person-group>: <article-title>Diabetes mellitus a risk for
osteoporosis?</article-title><source>Exp Clin Endocrinol Diabetes</source>,
<year>2001</year>, <volume>109</volume>: <fpage>S493</fpage>&#x02013;<lpage>S514</lpage>.
<pub-id pub-id-type="pmid">11460594</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Luan</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Ouyang</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>: <article-title>[Changes in sexual hormones and bone metabolism disorder
in postmenopausal NIDDM patients]</article-title>. <source>J Tongji Med Univ</source>,
<year>1996</year>, <volume>16</volume>: <fpage>217</fpage>&#x02013;<lpage>219</lpage>, 233.
<pub-id pub-id-type="pmid">9389085</pub-id></mixed-citation></ref></ref-list></back></article>